|
- Neuralink — Pioneering Brain Computer Interfaces
In our clinical trials, people are using Neuralink devices to control computers and robotic arms with their thoughts This technology will restore autonomy to those with unmet medical needs and unlock new dimensions of human potential
- Updates - Neuralink
Neuralink is developing a fully-implanted, wireless, high-channel count, brain-computer interface (BCI) with the goal of enabling people with paralysis to directly use their neural activity to operate computers and mobile devices with speed and ease
- Technology | Neuralink
Advanced, custom, low-power chips and electronics process neural signals, transmitting them wirelessly to the Neuralink Application, which decodes the data stream into actions and intents
- Two Years of Telepathy | Updates | Neuralink
Neuralink is building brain-computer interfaces (BCI) that will return autonomy to people with unmet medical needs Our first product, Telepathy, aims to enable people with paralysis to directly control computers, phones, and robotic limbs using their thoughts alone
- Neuralink raises $650 million Series E | Updates | Neuralink
Welcoming our first pioneers: Five individuals with severe paralysis are now using Neuralink to control digital and physical devices with their thoughts, marking a profound step toward helping restore independence
- A Year of Telepathy | Updates | Neuralink
Over the past year, three people with paralysis have received Neuralink implants This blog post explores how each person is using Telepathy in everyday life
- PRIME Study Progress Update | Updates | Neuralink
An exploded view of the N1 Implant Signals acquired by the electrodes are routed to electronics contained in the enclosure of the N1 Implant, which process and wirelessly transmit the neural data to an instance of the Neuralink Application running on an external device, such as a computer
- Neuralink’s First-in-Human Clinical Trial is Open for Recruitment
Neuralink’s First-in-Human Clinical Trial is Open for Recruitment We are happy to announce that we’ve received approval from the reviewing independent institutional review board and our first hospital site to begin recruitment for our first-in-human clinical trial
|
|
|